AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High Dose
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes type1
Conditions
Diabetes type1
Trial Timeline
Oct 24, 2018 → Oct 13, 2021
NCT ID
NCT03751007About AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High Dose
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High Dose is a phase 1/2 stage product being developed by Precigen for Diabetes type1. The current trial status is completed. This product is registered under clinical trial identifier NCT03751007. Target conditions include Diabetes type1.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes type1 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
9
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03751007 | Phase 1/2 | Completed |
Competing Products
20 competing products in Diabetes type1